相关实验视频

Updated: Mar 7, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

罗沙杜沙特通过调节CX43/ZO-1信号通路来改善脏间歇性纤维化

Wanru Yin¹, Guoyu Wang², Hanlei Zhou³

¹Department of Nephropathy, Shenyang Medical College Affiliated Central Hospital, Shenyang, 110075, China.

European journal of medical research

|March 5, 2026

概括

罗沙杜沙特 (FG4592) 可能通过稳定Hif-1α和改善细胞结 protein来保护纤维化. 这项研究表明,FG4592可能是慢性病和间纤维化的一种有前途的治疗方法.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

慢性病 (CKD) 是一种流行病,常见的结果是间纤维化 (RIF).
RIF的确切原因尚不清楚,需要进一步研究治疗干预措施.
低氧诱导因子酸酶抑制剂 (HIF-PHI) Roxadustat (FG4592) 在治疗慢性病相关贫血方面具有潜力,但其减轻损伤的机制需要阐明.

研究的目的:

调查FG4592预治疗对纤维化发展的保护作用.
阐明FG4592可能防止或逆转RIF的潜在机制.
在功能障碍和纤维化模型中评估FG4592的治疗潜力.

主要方法:

使用生物信息学分析,为FG4592.2.FG4592.FG4592.FG4592.FG4592.FG4592.FG4592.
在体外研究中,利用暴露于转化生长因子β (TGF-β) 的人类-2 (HK-2) 细胞来评估FG4592的保护作用.
用叶酸 (FA) 诱导的功能障碍模型来评估FG4592的活体疗效.

主要成果:

发现FG4592的预处理稳定了Hif-1α的表达.
FG4592促进了紧密结合蛋白 (connexin43 [CX43],zonula occludens-1 [ZO-1]) 和粘附分子E-cadherin的表达.
FG4592预治疗改善了TGF-β诱导的HK-2细胞损伤,改善了FA诱导的功能障碍,减少了炎症性细胞因子,恢复了功能.

结论:

FG4592显示出对叶酸诱导的功能障碍的屏蔽作用.
FG4592激活了Gap Junction信号通路,涉及CX43和ZO-1,以增强管状上皮细胞的修复.
FG4592提出了一种有前途的治疗策略,可以减缓CKD纤维化进展.

关键词:

慢性脏疾病慢性脏疾病导致缺氧的诱导因素脏间歇性纤维化脏间歇性纤维化罗哈德斯塔特斯塔特 (罗哈德斯塔特斯塔特) 在

更多相关视频

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...